Literature DB >> 31331910

DIS3L2 Promotes Progression of Hepatocellular Carcinoma via hnRNP U-Mediated Alternative Splicing.

Songge Xing1,2, Zhaoyong Li2, Wenhao Ma2, Xiaoping He2, Shengqi Shen2, Haoran Wei2, Shi-Ting Li2, Ying Shu1, Linchong Sun2,3, Xiuying Zhong2,3, Yuhao Huangfu2, Lanhong Su2, Junru Feng2, Xiaozhang Zhang2, Ping Gao2,3, Wei-Dong Jia4, Huafeng Zhang4,2.   

Abstract

DIS3-like 3'-5' exoribonuclease 2 (DIS3L2) degrades aberrant RNAs, however, its function in tumorigenesis remains largely unexplored. Here, aberrant DIS3L2 expression promoted human hepatocellular carcinoma (HCC) progression via heterogeneous nuclear ribonucleoproteins (hnRNP) U-mediated alternative splicing. DIS3L2 directly interacted with hnRNP U through its cold-shock domains and promoted inclusion of exon 3b during splicing of pre-Rac1 independent of its exonuclease activity, yielding an oncogenic splicing variant, Rac1b, which is known to stimulate cellular transformation and tumorigenesis. DIS3L2 regulated alternative splicing by recruiting hnRNP U to pre-Rac1. Rac1b was critical for DIS3L2 promotion of liver cancer development both in vitro and in vivo. Importantly, DIS3L2 and Rac1b expression highly correlated with HCC progression and patient survival. Taken together, our findings uncover an oncogenic role of DIS3L2, in which it promotes liver cancer progression through a previously unappreciated mechanism of regulating hnRNP U-mediated alterative splicing. SIGNIFICANCE: These findings establish the role and mechanism of the 3'-5' exoribonuclease DIS3L2 in hepatocellular carcinoma carcinogenesis. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31331910     DOI: 10.1158/0008-5472.CAN-19-0376

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Nuclear poly(A) binding protein 1 (PABPN1) mediates zygotic genome activation-dependent maternal mRNA clearance during mouse early embryonic development.

Authors:  Long-Wen Zhao; Ye-Zhang Zhu; Yun-Wen Wu; Shuai-Bo Pi; Li Shen; Heng-Yu Fan
Journal:  Nucleic Acids Res       Date:  2022-01-11       Impact factor: 16.971

Review 2.  The Key Role of RNA Modification in Breast Cancer.

Authors:  Yang Liu; Tong Zhu; Yi Jiang; Jiawen Bu; Xudong Zhu; Xi Gu
Journal:  Front Cell Dev Biol       Date:  2022-06-01

3.  The Construction of Bone Metastasis-Specific Prognostic Model and Co-expressed Network of Alternative Splicing in Breast Cancer.

Authors:  Runzhi Huang; Juanru Guo; Penghui Yan; Suna Zhai; Peng Hu; Xiaolong Zhu; Jiayao Zhang; Yannan Qiao; Yu Zhang; Hui Liu; Ling Huang; Jie Zhang; Daoke Yang; Zongqiang Huang
Journal:  Front Cell Dev Biol       Date:  2020-08-25

4.  Characterization of progression-related alternative splicing events in testicular germ cell tumors.

Authors:  Chuan-Jie Zhang; Zong-Tai Li; Kan-Jie Shen; Lu Chen; Dan-Feng Xu; Yi Gao
Journal:  Asian J Androl       Date:  2021 May-Jun       Impact factor: 3.285

5.  The Perlman syndrome DIS3L2 exoribonuclease safeguards endoplasmic reticulum-targeted mRNA translation and calcium ion homeostasis.

Authors:  Mehdi Pirouz; Chih-Hao Wang; Qi Liu; Aref G Ebrahimi; Farnaz Shamsi; Yu-Hua Tseng; Richard I Gregory
Journal:  Nat Commun       Date:  2020-05-26       Impact factor: 14.919

6.  Identification of Prognostic and Metastatic Alternative Splicing Signatures in Kidney Renal Clear Cell Carcinoma.

Authors:  Tong Meng; Runzhi Huang; Zhiwei Zeng; Zongqiang Huang; Huabin Yin; ChenChen Jiao; Penghui Yan; Peng Hu; Xiaolong Zhu; Zhenyu Li; Dianwen Song; Jie Zhang; Liming Cheng
Journal:  Front Bioeng Biotechnol       Date:  2019-10-15

7.  A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing.

Authors:  Xiaozhu Tang; Zhendong Deng; Pinggang Ding; Wanting Qiang; Yue Lu; Shengyao Gao; Ye Hu; Ye Yang; Juan Du; Chunyan Gu
Journal:  J Exp Clin Cancer Res       Date:  2022-03-08

8.  The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma.

Authors:  Cunjie Chang; Muthukumar Rajasekaran; Yiting Qiao; Heng Dong; Yu Wang; Hongping Xia; Amudha Deivasigamani; Minjie Wu; Karthik Sekar; Hengjun Gao; Mengqing Sun; Yuqin Niu; Qian Li; Lin Tao; Zhen Yan; Menglan Wang; Shasha Chen; Shujuan Zhao; Dajing Chen; Lina Li; Fan Yang; Haojin Gao; Baodong Chen; Ling Su; Liang Xu; Ye Chen; Veerabrahma Pratap Seshachalam; Gongxing Chen; Jayantha Gunaratne; Wanjin Hong; Junping Shi; Gongying Chen; David S Grierson; Benoit Chabot; Tian Xie; Kam Man Hui; Jianxiang Chen
Journal:  Nat Commun       Date:  2022-03-16       Impact factor: 17.694

9.  GPAA1 promotes the proliferation, invasion and migration of hepatocellular carcinoma cells by binding to RNA-binding protein SF3B4.

Authors:  Song Ge; Qiang Zhang; Xiaoyong Yang
Journal:  Oncol Lett       Date:  2022-03-22       Impact factor: 2.967

10.  Vital and Distinct Roles of H2A.Z Isoforms in Hepatocellular Carcinoma.

Authors:  Shaomei Tang; Xiaoliang Huang; Xi Wang; Xianguo Zhou; Huan Huang; Liwen Qin; Hongyu Tao; Qiuyan Wang; Yuting Tao
Journal:  Onco Targets Ther       Date:  2020-05-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.